N. Munoz, F. Bosch, S. De-sanjose, R. Herrero, X. Castellsague et al., Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer, New England Journal of Medicine, vol.348, issue.6, pp.518-545, 2003.
DOI : 10.1056/NEJMoa021641

J. Walboomers, M. Jacobs, M. Manos, F. Bosch, J. Kummer et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, The Journal of Pathology, vol.89, issue.1, pp.12-21, 1999.
DOI : 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F

M. Favre, F. Breitburd, O. Croissant, and G. Orth, Structural polypeptides of rabbit, bovine, and human papillomaviruses, J Virol, vol.15, pp.1239-1286, 1975.

C. Buck, N. Cheng, C. Thompson, D. Lowy, A. Steven et al., Arrangement of L2 within the Papillomavirus Capsid, Journal of Virology, vol.82, issue.11, pp.5190-5197, 2008.
DOI : 10.1128/JVI.02726-07

F. Breitburd, R. Kirnbauer, N. Hubbert, B. Nonnenmacher, C. Trin-dinh-desmarquet et al., Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection, J Virol, vol.69, pp.3959-63, 1995.

J. Suzich, S. Ghim, F. Palmer-hill, W. White, J. Tamura et al., Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas., Proceedings of the National Academy of Sciences, vol.92, issue.25, pp.11553-11560, 1995.
DOI : 10.1073/pnas.92.25.11553

R. Roden, E. Weissinger, D. Henderson, F. Booy, R. Kirnbauer et al., Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins, J Virol, vol.68, pp.7570-7574, 1994.

R. Roden, H. Greenstone, R. Kirnbauer, F. Booy, J. J. Lowy et al., In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype, J Virol, vol.70, pp.5875-83, 1996.

N. Christensen, R. Kirnbauer, J. Schiller, S. Ghim, R. Schlegel et al., Human Papillomavirus Types 6 and 11 Have Antigenically Distinct Strongly Immunogenic Conformationally Dependent Neutralizing Epitopes, Virology, vol.205, issue.1, pp.329-364, 1994.
DOI : 10.1006/viro.1994.1649

W. White, S. Wilson, W. Bonnez, R. Rose, S. Koenig et al., In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16, J Virol, vol.72, pp.959-64, 1998.

T. Giroglou, M. Sapp, C. Lane, C. Fligge, N. Christensen et al., Immunological analyses of human papillomavirus capsids, Vaccine, vol.19, issue.13-14, pp.1783-93, 2001.
DOI : 10.1016/S0264-410X(00)00370-4

A. Combita, A. Touzé, L. Bousarghin, N. Christensen, and P. Coursaget, Identification of Two Cross-Neutralizing Linear Epitopes within the L1 Major Capsid Protein of Human Papillomaviruses, Journal of Virology, vol.76, issue.13, pp.6480-6486, 2002.
DOI : 10.1128/JVI.76.13.6480-6486.2002

M. Mclaughlin-drubin, S. Wilson, B. Mullikin, J. Suzich, and C. Meyers, Human papillomavirus type 45 propagation, infection, and neutralization, Virology, vol.312, issue.1, pp.1-7, 2003.
DOI : 10.1016/S0042-6822(03)00312-X

K. Ault, . The-future, . Ii-study, and . Group, Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials, The Lancet, vol.369, issue.9576, pp.1861-1869, 2007.
DOI : 10.1016/S0140-6736(07)60852-6

J. Paavonen, D. Jenkins, F. Bosch, P. Naud, J. Salmerón et al., Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial, The Lancet, vol.369, issue.9580, pp.2161-70, 2007.
DOI : 10.1016/S0140-6736(07)60946-5

A. Ferenczy and E. Franco, Prophylactic human papillomavirus vaccines: potential for sea change, Expert Review of Vaccines, vol.6, issue.4, pp.511-536, 2007.
DOI : 10.1586/14760584.6.4.511

N. Christensen, J. Kreider, N. Kan, and S. Diangelo, The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes, Virology, vol.181, issue.2, pp.572-581, 1991.
DOI : 10.1016/0042-6822(91)90890-N

Y. Lin, L. Borenstein, R. Selvakumar, R. Ahmed, and F. Wettstein, Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus, Virology, vol.187, issue.2, pp.612-621, 1992.
DOI : 10.1016/0042-6822(92)90463-Y

L. Chandrachud, G. Grindlay, G. Mcgarvie, O. Neil, B. Wagner et al., Vaccination of Cattle with the N-Terminus of L2 Is Necessary and Sufficient for Preventing Infection by Bovine Papillomavirus-4, Virology, vol.211, issue.1, pp.204-212, 1995.
DOI : 10.1006/viro.1995.1392

J. Gaukroger, L. Chandrachud, O. Neil, B. Grindlay, G. Knowles et al., Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies, Journal of General Virology, vol.77, issue.7, pp.1577-83, 1996.
DOI : 10.1099/0022-1317-77-7-1577

M. Campo, O. Neil, B. Grindlay, G. Curtis, F. Knowles et al., A Peptide Encoding a B-Cell Epitope from the N-Terminus of the Capsid Protein L2 of Bovine Papillomavirus-4 Prevents Disease, Virology, vol.234, issue.2, pp.261-267, 1997.
DOI : 10.1006/viro.1997.8649

R. Roden, W. Yutzy, R. Fallon, S. Inglis, D. Lowy et al., Minor Capsid Protein of Human Genital Papillomaviruses Contains Subdominant, Cross-Neutralizing Epitopes, Virology, vol.270, issue.2, pp.254-261, 2000.
DOI : 10.1006/viro.2000.0272

M. Embers, L. Budgeon, M. Pickel, and N. Christensen, Protective Immunity to Rabbit Oral and Cutaneous Papillomaviruses by Immunization with Short Peptides of L2, the Minor Capsid Protein, Journal of Virology, vol.76, issue.19, pp.9798-805, 2002.
DOI : 10.1128/JVI.76.19.9798-9805.2002

R. Gambhira, P. Gravitt, I. Bossis, P. Stern, R. Viscidi et al., Vaccination of Healthy Volunteers with Human Papillomavirus Type 16 L2E7E6 Fusion Protein Induces Serum Antibody that Neutralizes across Papillomavirus Species, Cancer Research, vol.66, issue.23, pp.11120-11124, 2006.
DOI : 10.1158/0008-5472.CAN-06-2560

H. Alphs, R. Gambhira, B. Karanam, J. Roberts, S. Jagu et al., Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2, Proceedings of the National Academy of Sciences, vol.105, issue.15, pp.5850-5855, 2008.
DOI : 10.1073/pnas.0800868105

B. Karanam, R. Gambhira, S. Peng, S. Jagu, D. Kim et al., Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity, Vaccine, vol.27, issue.7, pp.1040-1049, 2009.
DOI : 10.1016/j.vaccine.2008.11.099

W. Shi, J. Liu, Y. Huang, and L. Qiao, Papillomavirus Pseudovirus: a Novel Vaccine To Induce Mucosal and Systemic Cytotoxic T-Lymphocyte Responses, Journal of Virology, vol.75, issue.21, pp.10139-10187, 2001.
DOI : 10.1128/JVI.75.21.10139-10148.2001

V. Renoux, M. Fleury, L. Bousarghin, J. Gaitan, P. Sizaret et al., Induction of antibody response against hepatitis E virus (HEV) with recombinant human papillomavirus pseudoviruses expressing truncated HEV capsid proteins in mice, Vaccine, vol.26, issue.51, pp.6602-6609, 2008.
DOI : 10.1016/j.vaccine.2008.09.035

C. Schellenbacher, R. Roden, and R. Kirnbauer, Chimeric L1-L2 Virus-Like Particles as Potential Broad-Spectrum Human Papillomavirus Vaccines, Journal of Virology, vol.83, issue.19, pp.10085-95, 2009.
DOI : 10.1128/JVI.01088-09

M. Fleury, A. Touze, E. Alvarez, G. Carpentier, C. Clavel et al., Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31, Archives of Virology, vol.18, issue.8, pp.1511-1534, 2006.
DOI : 10.1007/s00705-006-0734-y

A. Touze, S. Mehdaoui, P. Sizaret, C. Mougin, N. Munoz et al., The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system, J Clin Microbiol, vol.36, pp.2046-51, 1998.

A. Combita, A. Touze, L. Bousarghin, P. Sizaret, N. Munoz et al., Gene transfer using human papillomavirus pseudovirions varies according to virus genotype and requires cell surface heparan sulfate, FEMS Microbiology Letters, vol.204, issue.1, pp.183-191, 2001.
DOI : 10.1111/j.1574-6968.2001.tb10883.x

C. Buck, D. Pastrana, D. Lowy, and J. Schiller, Generation of HPV Pseudovirions Using Transfection and Their Use in Neutralization Assays, Methods Mol Med, vol.119, pp.445-62, 2005.
DOI : 10.1385/1-59259-982-6:445

C. Buck, D. Pastrana, D. Lowy, and J. Schiller, Efficient Intracellular Assembly of Papillomaviral Vectors, Journal of Virology, vol.78, issue.2, pp.751-758, 2004.
DOI : 10.1128/JVI.78.2.751-757.2004

M. Fleury, A. Touzé, S. De-sanjosé, F. Bosch, J. Klaustermeiyer et al., Detection of Human Papillomavirus Type 31-Neutralizing Antibodies from Naturally Infected Patients by an Assay Based on Intracellular Assembly of Luciferase-Expressing Pseudovirions, Clinical and Vaccine Immunology, vol.15, issue.1, pp.172-177, 2008.
DOI : 10.1128/CVI.00292-07

S. Voss and A. Skerra, Mutagenesis of a flexible loop in streptavidin leads to higher affinity for the Strep-tag II peptide and improved performance in recombinant protein purification, Protein Engineering Design and Selection, vol.10, issue.8, pp.975-82, 1997.
DOI : 10.1093/protein/10.8.975

A. Touzé and P. Coursaget, In vitro gene transfer using human papillomavirus-like particles, Nucleic Acids Research, vol.26, issue.5, pp.1317-1340, 1998.
DOI : 10.1093/nar/26.5.1317

L. Bousarghin, A. Touzé, G. Gaud, S. Iochmann, E. Alvarez et al., Inhibition of cervical cancer cell growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAs, Molecular Cancer Therapeutics, vol.8, issue.2, pp.357-65, 2009.
DOI : 10.1158/1535-7163.MCT-08-0626

R. Kirnbauer, F. Booy, N. Cheng, D. Lowy, and J. Schiller, Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic., Proceedings of the National Academy of Sciences, vol.89, issue.24, pp.12180-12184, 1992.
DOI : 10.1073/pnas.89.24.12180

T. Culp and N. Christensen, Kinetics of in vitro adsorption and entry of papillomavirus virions, Virology, vol.319, issue.1, pp.152-61, 2004.
DOI : 10.1016/j.virol.2003.11.004

M. Gaspariae, I. Rubio, N. Thönes, L. Gissmann, and M. Müller, Prophylactic DNA immunization against multiple papillomavirus types, Vaccine, vol.25, issue.23, pp.4540-53, 2007.
DOI : 10.1016/j.vaccine.2007.04.001

K. Becker, L. Florin, C. Sapp, and M. Sapp, Dissection of human papillomavirus type 33 L2 domains involved in nuclear domains (ND) 10 homing and reorganization, Virology, vol.314, issue.1, pp.161-168, 2003.
DOI : 10.1016/S0042-6822(03)00447-1

M. Okun, P. Day, H. Greenstone, F. Booy, D. Lowy et al., L1 Interaction Domains of Papillomavirus L2 Necessary for Viral Genome Encapsidation, Journal of Virology, vol.75, issue.9, pp.4332-4374, 2001.
DOI : 10.1128/JVI.75.9.4332-4342.2001